

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Dianette 2 mg/35 microgram coated tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 2.0 mg cyproterone acetate and 0.035 mg ethinylestradiol.

Excipients: contains lactose (as monohydrate) and sucrose

For a full list of excipients, see section 6.1

## 3 PHARMACEUTICAL FORM

Coated tablet (tablet).

*Product imported from Romania*

Beige, sugar-coated, biconvex tablets.

## 4 CLINICAL PARTICULARS

As per PA1410/003/001

## 5 PHARMACOLOGICAL PROPERTIES

As per PA1410/003/001

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

#### **Core**

Lactose monohydrate

Maize starch

Povidone K25

Magnesium stearate

Talc

#### **Tablet Coating**

Sucrose

Povidone K90

Macrogol 6000

Calcium carbonate

Talc

Glycerol 85%

Titanium dioxide (E 171)

Iron oxide yellow (E 172)

Montanglycol wax

### 6.2 Incompatibilities

Not applicable.

### **6.3 Shelf life**

The shelf life expiry date for this product shall be the date shown on the blister and outer package of the product on the market in the country of origin.

### **6.4 Special precautions for storage**

Store below 30°C.

### **6.5 Nature and contents of container**

Dianette tablets are contained in blister packs consisting of the following standard pharmaceutical packaging material: Deep drawn strips made of polyvinyl chloride film with counter-sealing foil made of aluminium with heat sealable coating.

*Presentation:*

Calendar-pack containing 21 tablets.

### **6.6 Special precautions for disposal**

No special requirements.

## **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Lexon Pharmaceuticals (Ireland) Limited  
Block 3  
Harcourt Centre  
Harcourt Road  
Dublin 2  
Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA23176/033/001

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 14<sup>th</sup> August 2020

## **10 DATE OF REVISION OF THE TEXT**

October 2021